DSS, Inc. to Present at Emerging Growth Conference April 19 at 1:45 PM
17 avr. 2023 10h00 HE
|
DSS, Inc.
ROCHESTER, N.Y., April 17, 2023 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses in diversified market sectors and strategically acquiring and...
DSS Announces Letter to Shareholders
02 mars 2023 08h30 HE
|
DSS, Inc.
ROCHESTER, N.Y., March 02, 2023 (GLOBE NEWSWIRE) -- DSS, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational company operating nine business divisions through strategic acquisitions...
Impact BioMedical Scientific Partner GRDG Sciences to be Featured in New Documentary
19 oct. 2022 08h00 HE
|
DSS, Inc.
Impact BioMedical is a wholly owned subsidiary of DSS “A Real-Life Mission Impossible” — Global Research and Discovery Group steps in the spotlight for documentary, “The BioQuest” — Filming to...
DSS Receives New York Stock Exchange Notice Regarding Late Form 10-Q Filing
30 août 2022 16h45 HE
|
DSS, Inc.
ROCHESTER, N.Y., Aug. 30, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing...
Impact BioMedical Develops Quantum Antihistamine
26 juil. 2022 08h00 HE
|
DSS, Inc.
ROCHESTER, N.Y., July 26, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing...
DSS Announces Licensing of Impact BioMedical’s Linebacker Portfolio to ProPhase Labs
21 juil. 2022 17h00 HE
|
DSS, Inc.
ROCHESTER, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing...
DSS Strengthens and Expands Board with Appointment of Two Independent Directors
13 juil. 2022 08h00 HE
|
DSS, Inc.
ROCHESTER, N.Y., July 13, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing...
Impact BioMedical Announces License Agreement with ProPhase Labs to Produce and Distribute Viral-Fighting Compound Equivir
28 juin 2022 08h00 HE
|
DSS, Inc.
HENRIETTA, N.Y., June 28, 2022 (GLOBE NEWSWIRE) -- Impact Biomedical, Inc., a wholly owned subsidiary of DSS, Inc. (NYSE American: DSS), along with its scientific research partner Global Research...
DSS’s Impact BioMedical Receives China Patent for its Functional Fragrance Formulation Mosquito Repellant
07 juin 2022 07h00 HE
|
DSS, Inc.
HENRIETTA, N.Y., June 07, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically...
DSS, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®
06 mai 2022 08h30 HE
|
DSS, Inc.
ROCHESTER, N.Y., May 06, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing assets...